You are here

Article info

Article menu
Download PDFPDF
Commentary
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

Authors

  1. Correspondence to Dr Carmen Berasain, Division of Hepatology and Gene Therapy, CIMA, Universidad de Navarra, Avda. Pio XII 55, Pamplona 31008, Spain; cberasain{at}unav.es
View Full Text

Citation

Berasain C
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Gut 2013;62:1674-1675.

Publication history

  • Received February 18, 2013
  • Accepted February 19, 2013
  • First published March 12, 2013.
Online issue publication 
April 18, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions